Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

These ASX All Ords shares have soared 16% to 37% already in 2025. The post 3 ASX All Ords shares leading the charge in 2025 ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) had its price target dropped by equities researchers at Bank of America from $13.00 to $11.00 in a research report issued to clients and investors ...

HONG KONG, Jan 9, 2025 - (ACN Newswire) – The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...